Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA.3: Tarceva plus Gemcitabine in Pancreatic Cancer
NCT00040183Phase 3Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Nov 2001
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Tarceva + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Overall Survival. Started Nov 2001; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00040183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040183.